Fexofenadine - sanofi-aventis

Drug Profile

Fexofenadine - sanofi-aventis

Alternative Names: Allegra; Allegra-D; Fexofenadine; Fexohf-1-96; M016455; MDL 16455; MDL 16455A; Telfast; Telfast 120; Telfast 180; TelfastPaediatric; Terfenadine acid metabolite; Terfenadine carboxylate

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Acetic acids; Antiallergics; Benzhydryl compounds; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis; Dermatitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
  • Discontinued Asthma

Most Recent Events

  • 17 Sep 2018 Phase-III clinical trials in Seasonal allergic rhinitis in Canada (PO) (NCT03664882)
  • 11 Sep 2018 Sanofi plans a phase III FEXPOLSAR trial for Seasonal rhinitis (PO, Tablet) (NCT03664882)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top